Coherus (NASDAQ: CHRS) grants director 30k RSUs and 60k options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Coherus Oncology, Inc. reported that director Rita A. Karachun received equity compensation on June 5, 2026. She was granted 30,000 restricted stock units (RSUs), each convertible into one share of common stock upon vesting, with 100% of the RSUs vesting on the one year anniversary of June 3, 2026, subject to her continued service. She was also granted a stock option for 60,000 shares of common stock at an exercise price of $1.45 per share, which vests and becomes exercisable in full on June 3, 2027, subject to continued service. Following these awards, she holds 30,000 shares of common stock and 60,000 stock options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Karachun Rita A
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 60,000 | $0.00 | -- |
| Grant/Award | Common Stock | 30,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 60,000 shares (Direct, null);
Common Stock — 30,000 shares (Direct, null)
Footnotes (1)
- Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date. The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date.
Key Figures
RSU grant: 30,000 RSUs
RSU vesting date reference: One year anniversary of June 3, 2026
Stock option grant: 60,000 options
+4 more
7 metrics
RSU grant
30,000 RSUs
Grant to director Rita A. Karachun on June 5, 2026
RSU vesting date reference
One year anniversary of June 3, 2026
100% of RSUs vest on this date, subject to continued service
Stock option grant
60,000 options
Grant to purchase Coherus common stock
Option exercise price
$1.45 per share
Exercise price for 60,000 stock options
Option vesting date
June 3, 2027
Options vest and become exercisable in full on this date
Shares held after grant
30,000 shares
Total Coherus common shares held directly after transactions
Options held after grant
60,000 options
Total stock options held directly after transactions
Key Terms
restricted stock units ("RSUs"), Stock Option (Right to Buy), exercise price, vesting
4 terms
restricted stock units ("RSUs") financial
"Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with an exercise price of 1.4500"
exercise price financial
"conversion_or_exercise_price": "1.4500""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"100% of the RSUs shall vest on the one year anniversary of June 3, 2026"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What equity awards did Rita A. Karachun receive from Coherus (CHRS)?
Rita A. Karachun received 30,000 restricted stock units and a stock option for 60,000 shares. The option has a $1.45 exercise price and both awards are subject to future vesting and her continued service with Coherus Oncology, Inc.
When do Rita A. Karachun’s Coherus (CHRS) RSUs vest?
All 30,000 RSUs granted to Rita A. Karachun vest on the one year anniversary of June 3, 2026. Vesting is contingent on her maintaining a continued service relationship with Coherus Oncology, Inc. through that vesting date under the award terms.
What are the terms of Rita A. Karachun’s Coherus (CHRS) stock options?
She received a stock option covering 60,000 shares of Coherus common stock at a $1.45 exercise price. The underlying shares vest and become exercisable as to 100% of the total on June 3, 2027, subject to her continued service relationship with the company.
Is Rita A. Karachun’s Coherus (CHRS) Form 4 a stock purchase or compensation grant?
The Form 4 reflects compensation-related equity grants rather than an open-market stock purchase. She received 30,000 RSUs and 60,000 stock options at a $1.45 exercise price, both subject to future vesting based on her continued service with Coherus Oncology, Inc.